On Monday, Mirum Pharmaceuticals cleared a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 73 the day before.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Mirum Pharmaceuticals is building a cup without handle with a 35.56 entry. See if the stock can break out in volume at least 40% above average.
The company posted 0% earnings growth in the latest quarterly report, while sales growth came in at 119%.
Mirum Pharmaceuticals holds the No. 33 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
